[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359294-105":59,"doc-detail-359294-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","real-world-performance-of-hpv-dna-based-screening-in-health-resource-limited-areas-of-china-a-multicenter-implementation-study","Real-World Performance of HPV DNA-Based Screening in Health Resource-Limited Areas of China - A Multicenter Implementation Study","","Cervical cancer remains a major public health burden in China, and limited-resource counties face barriers to adopting HPV DNA as a primary screening test due to funding constraints for reagents and laboratory platforms. A multicenter study in 10 pilot counties evaluated HPV DNA–based strategies using project-supported reagents, platforms, and training. Results compared cytology alone with HPV DNA testing plus cytology triage or VIA/VILI triage across key performance indicators, including CIN2+ detection and referral efficiency.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/real-world-performance-of-hpv-dna-based-screening-in-health-resource-limited-areas-of-china-a-multicenter-implementation-study/359294/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/real-world-performance-of-hpv-dna-based-screening-in-health-resource-limited-areas-of-china-a-multicenter-implementation-study/359294.png","ImageObject",300,407,{"name":92,"@type":93},"Jacob","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What screening strategies were compared in the multicenter study?","Question",{"text":113,"@type":114},"The study compared cytology alone; HPV DNA testing with cytology triage; and HPV DNA testing with VIA/VILI triage for secondary triage.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which indicators were used to assess screening performance?",{"text":118,"@type":114},"Key indicators included screen positivity rate, colposcopy rate, CIN2+ detection, positive predictive value (PPV), and number needed to refer (NNR), with inverse probability weighting to address loss to follow-up.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the main findings regarding HPV DNA–based strategies?",{"text":122,"@type":114},"HPV-based strategies outperformed cytology across indicators, with higher CIN2+ detection and referral efficiency, and reduced loss to follow-up under the HPV + VIA/VILI approach.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},359294,1790474860,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41,"preview_page_count":19,"preview_urls":146},962084931830,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Real-World Performance of HPV DNA–Based Screening in Health Resource–Limited Areas of China: A Multicenter Implementation Study  \nXinhua Jia1,2, Xi’ao Da1,2, Jingyi Shi1,2, Mingyang Chen1, Rufei Duan3, Zhifang Li4, Ruimei Feng5, Chunxia Yang6, Hanyue Ding1, and Youlin Qiao1,2  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Background: Cervical cancer remains a significant health burden in China. National policies now allow human papillomavirus (HPV) DNA as a primary screening test, but many health resource–limited counties have not adopted it because programs cannot fund reagents or laboratory platforms. We conducted a multicenter study in 10 pilot counties where HPV DNA screening was introduced with project-supported reagents, platforms, and training.\u003Cbr>Methods: We analyzed data from 10 pilot counties designated by the National Cervical Cancer Prevention Program. A total of 63,223 women aged 35 to 64 years were screened with three strategies: (i) cytology alone,(ii) HPV DNA testing with cytology triage, and (iii) HPV DNA testing with visual inspection with acetic acid/Lugol iodine (VIA/VILI) triage. Key indicators included screen positivity rate, colposcopy rate, cervical intraepithelial neoplasia (CIN) 2+ detection, positive predictive value\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (PPV), and number needed to refer (NNR) . Inverse probability weighting was used to adjust for loss to follow-up.\u003Cbr>Results: HPV-based strategies were superior to cytology across all indicators. CIN2+ detection was two to three times higher, with the highest PPV in the HPV + cytology group (21.9%) and the lowest NNR (5.73), indicating higher referral efficiency. Loss to follow-up rate was also significantly reduced under the HPV + VIA/VILI strategy. These advantages were most prominent among women aged ≥45 years.\u003Cbr>Conclusions: Within the first year of implementation, HPV DNA–based screening is feasible and more effective in health resource–limited areas of China and flexible triage models can be adapted.\u003Cbr>Impact: The findings support the integration of HPV DNA testing into national cervical cancer screening programs and highlight needs for robust follow-up systems in underserved populations. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nCervical cancer remains a major global public health challenge, with approximately 661,021 new cases and 348,189 deaths reported in 2022 (1) . China alone accounts for nearly 22.7% of global incidence and 16% of cervical cancer–related deaths (2) . Burden is highly inequitable: countries in the lowest Human Development Index (HDI ≤0.55) strata experience double the incidence and fivefold higher mortality relative to high-HDI settings (3, 4) .  \n1School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. 2Department of Cancer Epidemiology, National Cancer Cen","cbCaifPzomCNV1TY","https://ap.wps.com/l/cbCaifPzomCNV1TY","pdf",5853645,12,"English","# Background\n# Methods\n# Results\n# Conclusions\n# Impact\n# Introduction","[{\"question\":\"What screening strategies were compared in the multicenter study?\",\"answer\":\"The study compared cytology alone; HPV DNA testing with cytology triage; and HPV DNA testing with VIA/VILI triage for secondary triage.\"},{\"question\":\"Which indicators were used to assess screening performance?\",\"answer\":\"Key indicators included screen positivity rate, colposcopy rate, CIN2+ detection, positive predictive value (PPV), and number needed to refer (NNR), with inverse probability weighting to address loss to follow-up.\"},{\"question\":\"What were the main findings regarding HPV DNA–based strategies?\",\"answer\":\"HPV-based strategies outperformed cytology across indicators, with higher CIN2+ detection and referral efficiency, and reduced loss to follow-up under the HPV + VIA/VILI approach.\"}]","Real-World Performance of HPV DNA-Based Screening in Health Resource-Limited Areas of China - A Multicenter Implementation Study | PDF",1790136620,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/357ca746c3108912519ad8e8cfce1e07.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/85973424520d7101b5383d678c69ebb2.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b2c28acfe9b4d82d42821202bbe2221.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb0995620aece5ecc92324d7a869965e.webp",980,1311]